[EN] 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR [FR] COMPOSÉS DE 4-PIPÉRAZINYLPYRIMIDINE CONVENANT POUR TRAITER DES TROUBLES QUI RÉPONDENT À UNE MODULATION DU RÉCEPTEUR D3 DE LA DOPAMINE
[EN] 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR [FR] COMPOSÉS DE 4-PIPÉRAZINYLPYRIMIDINE CONVENANT POUR TRAITER DES TROUBLES QUI RÉPONDENT À UNE MODULATION DU RÉCEPTEUR D3 DE LA DOPAMINE
The present invention relates to methods of making quinoline amides of Formula I below, which are microsomal triglyceride transfer protein inhibitors and can be used as medicines.
1
The present invention also relates to compounds that are used to make quinoline amides of Formula I and methods of making these compounds.
A process for the preparation of a .beta.-alkoxyacrylonitrile of the formula R'O--CH.dbd.CR--CN (C) where R is hydrogen or an alkyl moiety, among others, by contacting a compound of the formula (1/.alpha.Me) O--CH.dbd.CR--CN (A) where Me is an alkali metal or alkaline earth metal and .alpha. is 1 or 2 respectively, an elevated temperature with a halogen compound of the formula R'Hal (B) where R' is among others a straight or branched alkyl or alkenyl moiety and Hal represents chlorine, bromine, or iodine. Also disclosed is a process for preparing a 3-amino-acrylonitrile of the formula ##STR1## where R.sup.5 and R.sup.6 represent, among others, hydrogen, alkyl or alkenyl by contacting a 3-alkoxyacrylonitrile or a metal salt of 3-hydroxyacrylonitrile with ammonia and/or amine. Also disclosed is a process for the preparation of such 3-aminoacrylonitrile by contacting a 3-alkoxyacrylonitrile of the formula ##STR2## where R' has the meaning given above and R.sup.7 has the same meaning as R stated above with an amine of the formula ##STR3## wherein R.sup.5 and R.sup.6 represent among others hydrogen, alkyl or alkenyl. The application further discloses a process for preparing a 3-amino-acrylonitrile of the formula ##STR4## where R.sup.5, R.sup.6 and R.sup.7 have the above meanings by contacting a compound of the formula ##EQU1## with an amine. The Application also discloses the preparation of two-cyanovinyl esters by reaction of a cyanovinyl compound of the formula ##EQU2## with an acid halide or an acid anhydride.
7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B
申请人:——
公开号:US20020132806A1
公开(公告)日:2002-09-19
This invention relates to compounds of Formula I
1
that inhibit the secretion of apolipoprotein B, to pharmaceutical compositions comprising the compounds, and to methods of treating and/or preventing atherosclerosis, obesity, diabetes, hyperlipidemia, hyperliproproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia, pancreatitis, myocardial infarction, stroke, restenosis, or Syndrome X. This invention also relates to methods of reducing the secretion of apolipoprotein B and/or inhibiting microsomal triglyceride transfer protein.
7-[(4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B
申请人:Pfizer Inc
公开号:US06713489B2
公开(公告)日:2004-03-30
This invention relates to compounds of Formula I:
that inhibit the secretion of apolipoprotein B, to pharmaceutical compositions comprising the compounds, and to methods of treating and/or preventing atherosclerosis, obesity, diabetes, hyperlipidemia, hyperliproproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia, pancreatitis, myocardial infarction, stroke, restenosis, or Syndrome X. This invention also relates to methods of reducing the secretion of apolipoprotein B and/or inhibiting microsomal triglyceride transfer protein.
7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B
申请人:Pfizer, Inc.
公开号:US06369075B1
公开(公告)日:2002-04-09
This invention relates to compounds of Formula I
that inhibit the secretion of apolipoprotein B, to pharmaceutical compositions comprising the compounds, and to methods of treating and/or preventing atherosclerosis, obesity, diabetes, hyperlipidemia, hyperliproproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia, pancreatitis, myocardial infarction, stroke, restenosis, or Syndrome X. This invention also relates to methods of reducing the secretion of apolipoprotein B and/or inhibiting microsomal triglyceride transfer protein.